文献速递肿瘤 PET/CT放射性药物与辐射防护

68Ga-FAPI-04与18F-FDG在转移性乳腺癌临床前纵向PET成像中的比较

68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-28

该临床前纵向研究在4T1转移性乳腺癌小鼠模型中每周行68Ga-FAPI-04与18F-FDG PET成像至6周,评估两者在肿瘤转移全程的检测性能。结果显示68Ga-FAPI-04在转移早期敏感性优于18F-FDG,但随转移进展其摄取下降、敏感性低于18F-FDG,且两者摄取及S/B比值无直接相关性。

要点

  • 68Ga-FAPI-04在肿瘤转移早期较18F-FDG更敏感。
  • 随转移进展,68Ga-FAPI-04摄取下降且敏感性低于18F-FDG。
  • 转移过程中两种探针的摄取及S/B比值无直接相关性。

核心结论

  • 68Ga-FAPI-04在检测肿瘤转移早期比18F-FDG更敏感,但在转移晚期敏感性低于18F-FDG。

研究设计与样本

  • 对转移病灶进行H&E与免疫组化染色以评估FAP表达,并统计分析不同转移阶段两种探针摄取(%ID/cc)的相关性。

主要发现

  • 68Ga-FAPI-04在肿瘤转移早期敏感性高于18F-FDG。
  • 随肿瘤转移进展,68Ga-FAPI-04摄取下降并变得不如18F-FDG敏感。
  • 在动态转移过程中,68Ga-FAPI-04与18F-FDG的摄取或S/B比值之间无直接相关性。

临床怎么用

  • 临床前结果提示68Ga-FAPI-04可用于转移早期检测,但转移晚期需考虑18F-FDG或联合显像。
  • 结果有助于解释未来临床与临床前研究中68Ga-FAPI-04与18F-FDG的成像表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This longitudinal study aims to evaluate the performance of 68 Ga-FAPI-04 and 18F-FDG and to profile the dynamic process of tumor metastasis in a preclinical 4T1 breast cancer model. Although both of these two radioligands are wildly used in clinic, no study was reported on their performance in the longitudinal monitoring of tumor metastasis. Also, no correlation between the expression level of fibroblast activation protein (FAP) and the development of tumor metastasis has been elucidated previously. In this study, we evaluated the performance of 68 Ga-FAPI-04 and 18F-FDG PET during the entire process of tumor metastasis, and their potential for the early diagnosis of tumor metastasis. We also clarified the correlation of uptakes as well as the signal-to-background (S/B) ratios between these two probes at different stages of tumor metastasis. METHODS: Forty 4T1 metastatic breast cancer murine models were established using female BALB/c mice, followed by the longitudinal imaging with 68 Ga-FAPI-04 and 18F-FDG once a week for up to 6 weeks. In vitro hematoxylin and eosin (H&E) and immunochemistry (IHE) staining were performed to evaluate FAP expression on the metastatic lesions. Further statistical analysis was performed to evaluate the correlation of 68 Ga-FAPI-04 and 18F-FDG uptake (%ID/cc) at different stages of the metastasis. RESULTS: 68 Ga-FPAI-04 holds an advantage over 18F-FDG with higher sensitivity at the early stage of tumor metastasis. However, with the progress of tumor metastasis, uptake of 68 Ga-FAPI-04 decreases and becomes less sensitive than 18F-FDG. There is also no direct correlation between uptake or S/B ratios of 68 Ga-FAPI-04 and 18F-FDG during this dynamic process. CONCLUSION: 68 Ga-FAPI-04 is more sensitive than 18F-FDG in detecting the early stage of tumor metastasis, but becomes less sensitive than 18F-FDG at the late stage of tumor metastasis. We envision this result would be meaningful for the explanation of the 68 Ga-FAPI-04 and 18F-FDG imaging both in the future clinic and preclinic studies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ding F, Huang C, Liang C, et al. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34181060. doi:10.1007/s00259-021-05442-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。